Results A total of 4277 patients with non–dialysis-dependent CKD were randomized
(roxadustat, n= 2391; placebo, n= 1886). Baseline characteristics were comparable between …

Background: Although renal anemia has attracted widespread attention, a large proportion
of chronic kidney disease (CKD) patients with anemia still do not meet the hemoglobin (Hb) …

Aims Renal anaemia is a common complication of chronic kidney disease (CKD).
Roxadustat is the first‐in‐class oral hypoxia‐inducible factor prolyl hydroxylase inhibitor for …

Introduction This study evaluated efficacy and safety/tolerability of roxadustat, an oral
hypoxia-inducible factor prolyl hydroxylase inhibitor, in Japanese anemic non-dialysis …

Introduction This integrated phase 3 analysis examined efficacy and cardiovascular safety
for roxadustat vs erythropoiesis-stimulating agents (ESAs) in dialysis-dependent patients …

Abstract Background: Enarodustat (JTZ-951) is an oral hypoxia-inducible factor prolyl
hydroxylase inhibitor that mimics adaptive responses to hypoxic conditions and may provide …

Results Of the 145 patients enrolled, 143 were evaluable for efficacy. Overall, 92% of
patients achieved hemoglobin response. Higher compared with lower starting doses led to …

Abstract Roxadustat (Ai Rui Zhuo® in China) is an orally administered, small molecule
hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor that is being developed by …

Background Daprodustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor. In
patients with chronic kidney disease (CKD) who are not undergoing dialysis, the efficacy …

Background: Daprodustat is an oral agent that stimulates erythropoiesis by inhibiting the
prolyl hydroxylases which mark hypoxia-inducible factor for degradation through …